1. Center for Disease Control and Prevention . National diabetes statistics report; 2020. Published August 28, 2020. Accessed June 25, 2021. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
Google Scholar2. Kalra, S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355-366. doi:10.1007/s13300-014-0089-4.
Google Scholar | Crossref | Medline3. Garber, AJ, Handelsman, Y, Grunberger, G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26(1):107-139. doi:10.4158/CS-2019-0472.
Google Scholar | Crossref | Medline4. Nauck, MA, Del Prato, S, Meier, JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022. doi:10.2337/dc11-0606.
Google Scholar | Crossref | Medline | ISI5. Invokana (canagliflozin) . Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2021. Accessed May 28, 2021. https://www.janssenlabels.com/package-insert/product-patient-information/INVOKANA-medication-guide.pdf.
Google Scholar6. Farxiga (dapagliflozin) . Cambridge, England: AstraZeneca Pharmaceuticals LP; 2021. Accessed May 28, 2021. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf.
Google Scholar7. Jardiance (empagliflozin). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2021. Accessed May 28, 2021. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf.
Google Scholar8. Steglatro (ertugliflozin) . Whitehouse Station, NJ. Merck Sharp & Dohme Corp.; 2021. Accessed May 28, 2021. https://www.merck.com/product/usa/pi_circulars/s/steglatro/steglatro_pi.pdf.
Google Scholar9. Saisho, Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):14. doi:10.3390/diseases8020014.
Google Scholar | Crossref10. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720.
Google Scholar | Crossref | Medline | ISI11. Packer, M, Anker, SD, Butler, J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(6):671-680. doi:10.1093/eurheartj/ehaa968.
Google Scholar | Crossref | Medline12. Anker, SD, Butler, J, Filippatos, G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. doi:10.1056/NEJMoa2107038.
Google Scholar | Crossref | Medline13. Abraham, WT, Lindenfeld, J, Ponikowski, P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021;42(6):700-710. doi:10.1093/eurheartj/ehaa943.
Google Scholar | Crossref | Medline14. Neal, B, Perkovic, V, Mahaffey, K, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;337:644-657. doi:10.1056/NEJMoa1611925.
Google Scholar | Crossref15. Perkovic, V, Jardine, MJ, Neal, B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. doi:10.1056/NEJMoa1811744.
Google Scholar | Crossref | Medline16. Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357. doi:10.1056/NEJMoa1812389.
Google Scholar | Crossref | Medline17. McMurray, JJV, Solomon, SD, Inzucchi, SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. doi:10.1056/NEJMoa1911303.
Google Scholar | Crossref | Medline18. Heerspink, HJL, Stefánsson, BV, Correa-Rotter, R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446. doi:10.1056/NEJMoa2024816.
Google Scholar | Crossref | Medline19. Williams, DM, Evans, M. Dapagliflozin for heart failure with preserved ejection fraction: Will the DELIVER study deliver? Diabetes Ther. 2020;11(10):2207-2219. doi:10.1007/s13300-020-00911-0.
Google Scholar | Crossref | Medline20. ADA Standards—American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(suppl 1):S111-S124. doi:10.2337/dc21-S009.
Google Scholar | Crossref21. Arksey, H, O’Malley, L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19-32. doi:10.1080/1364557032000119616.
Google Scholar | Crossref22. Tricco, AC, Lillie, E, Zarin, W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850.
Google Scholar | Crossref | Medline23. Covidence systematic review software . Melbourne, Victoria, Australia: Veritas Health Innovation. www.covidence.org. Accessed May 1, 2021.
Google Scholar24. Inoue, H, Morino, K, Ugi, S, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial. J Diabetes Investig. 2019;10(4):1012-1021. doi:10.1111/jdi.12985.
Google Scholar | Crossref | Medline25. Ishihara, H, Yamaguchi, S, Sugitani, T, Kosakai, Y. Open-label study to assess the efficacy of ipragliflozin for reducing insulin dose in patients with type 2 diabetes mellitus receiving insulin therapy. Clin Drug Investig. 2019;39(12):1213-1221. doi:10.1007/s40261-019-00851-z.
Google Scholar | Crossref | Medline26. Sertbas, M, Sertbas, Y, Okuroglu, N, Akyildiz, AB, Sancak, S, Ozdemir, A. Efficacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin. Pak J Med Sci. 2019;35(2):399-403. doi:10.12669/pjms.35.2.21.
Google Scholar | Crossref | Medline27. Pujante, P, Ares, J, Maciá, C, Rodriguez Escobedo, R, Menéndez, E, Delgado, E. Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2. Med Clin (Barc). 2019;152(11):438-441. doi:10.1016/j.medcli.2018.09.019.
Google Scholar | Crossref | Medline28. Araki, E, Onishi, Y, Asano, M, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig. 2016;7(4):555-564. doi:10.1111/jdi.12453.
Google Scholar | Crossref | Medline29. Araki, E, Onishi, Y, Asano, M, Kim, H, Yajima, T. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab. 2017;19(4):562-570. doi:10.1111/dom.12853.
Google Scholar | Crossref | Medline30. Cefalu, WT, Leiter, LA, de Bruin, TW, Gause-Nilsson, I, Sugg, J, Parikh, SJ. Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38(7):1218-1227. doi:10.2337/dc14-0315.
Google Scholar | Crossref | Medline31. Leiter, LA, Cefalu, WT, de Bruin, TW, Gause-Nilsson, I, Sugg, J, Parikh, SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252-1262. doi:10.1111/jgs.12881.
Google Scholar | Crossref | Medline32. Rosenstock, J, Jelaska, A, Frappin, G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815-1823. doi:10.2337/dc13-3055.
Google Scholar | Crossref | Medline | ISI33. Rosenstock, J, Jelaska, A, Zeller, C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936-948. doi:10.1111/dom.12503.
Google Scholar | Crossref | Medline34. Terauchi, Y, Tamura, M, Senda, M, Gunji, R, Kaku, K. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017;19(10):1397-1407. doi:10.1111/dom.12957.
Google Scholar | Crossref | Medline35. Terauchi, Y, Tamura, M, Senda, M, Gunji, R, Kaku, K. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018;20(5):1176-1185. doi:10.1111/dom.13213.
Google Scholar | Crossref | Medline36. Wilding, JP, Norwood, P, T’joen, C, Bastien, A, List, JF, Fiedorek, FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656-1662. doi:10.2337/dc09-0517.
Google Scholar | Crossref | Medline | ISI37. Wilding, JP, Woo, V, Soler, NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003.
Google Scholar | Crossref | Medline | ISI38. Wilding, JP, Woo, V, Rohwedder, K, Sugg, J, Parikh, S; Dapagliflozin 006 Study Group . Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124-136. doi:10.1111/dom.12187.
Google Scholar | Crossref | Medline39. Yang, W, Ma, J, Li, Y, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial. J Diabetes. 2018;10(7):589-599. doi:10.1111/1753-0407.12634.
Google Scholar | Crossref | Medline40. UK Hypoglycaemia Study Group . Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-1147. doi:10.1007/s00125-007-0599-y.
Google Scholar | Crossref | Medline | ISI41. Gehlaut, RR, Dogbey, GY, Schwartz, FL, Marling, CR, Shubrook, JH. Hypoglycemia in type 2 diabetes—more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9:999-1005. doi:10.1177/1932296815581052.
Google Scholar | SAGE Journals42. Bonds, DE, Miller, ME, Bergenstal, RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
Google Scholar | Crossref43. Zoungas, S, Patel, A, Chalmers, J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418. doi:10.1056/NEJMoa1003795.
Google Scholar | Crossref | Medline | ISI44. Shanik, MH, Xu, Y, Skrha, J, Dankner, R, Zick, Y, Roth, J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31(suppl 2):S262-S268. doi:10.2337/dc08-s264.
Google Scholar |